GLPwatch

Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats.

Sci Rep · 2019

Last updated 2026-05-28

In a study on rats, daily injections of the GLP-1 drug liraglutide for 15 days helped prevent high blood pressure from developing. The drug also reduced levels of norepinephrine, a chemical linked to stress responses, and activated specific brainstem areas. When a part of the brainstem linked to blood pressure control was damaged, the drug’s ability to lower blood pressure was weakened.

AI summary of the abstract below.

JournalSci Rep, 2019
Citations34
Relative citation ratio1.55
NIH percentile66
Molecules
Conditions studied Cardiovascular Risk Reduction

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists, widely used to treat type 2 diabetes, reduce blood pressure (BP) in hypertensive patients. Whether this action involves central mechanisms is unknown. We here report that repeated lateral ventricular (LV) injection of GLP-1R agonist, liraglutide, once daily for 15 days counteracted the development of hypertension in spontaneously hypertensive rats (SHR). In parallel, it suppressed urinary norepinephrine excretion, and induced c-Fos expressions in the area postrema (AP) and nucleus tractus solitarius (NTS) of brainstem including the NTS neurons immunoreactive to dopamine beta-hydroxylase (DBH). Acute administration of liraglutide into fourth ventricle, the area with easy access to the AP and NTS, transiently decreased BP in SHR and this effect was attenuated after lesion of NTS DBH neurons with anti-DBH conjugated to saporin (anti-DBH-SAP). In anti-DBH-SAP injected SHR, the antihypertensive effect of repeated LV injection of liraglutide for 14 days was also attenuated. These findings demonstrate that the central GLP-1R signaling via NTS DBH neurons counteracts the development of hypertension in SHR, accompanied by attenuated sympathetic nerve activity.

Verbatim abstract via PubMed 31537818 ↗